PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34830377-4 2021 Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs), including erlotinib, gefitinib, and osimertinib, are effective therapeutic agents in EGFR-mutated NSCLC. Gefitinib 74-83 epidermal growth factor receptor Rattus norvegicus 8-12 12219038-7 2002 In other experiments, a specific EGFR inhibitor (ZD1839) was added and cell growth determined over 5 days. Gefitinib 49-55 epidermal growth factor receptor Rattus norvegicus 33-37 11479217-1 2001 Several inhibitors of EGF receptor (EGFR) tyrosine kinase activity have been developed that compete with ATP at its binding site such as the quinazolines PD 153035 and ZD 1839 or the 4,5-dianilino-phthalimides DAPH1 and DAPH2. Gefitinib 168-175 epidermal growth factor receptor Rattus norvegicus 22-34 11479217-1 2001 Several inhibitors of EGF receptor (EGFR) tyrosine kinase activity have been developed that compete with ATP at its binding site such as the quinazolines PD 153035 and ZD 1839 or the 4,5-dianilino-phthalimides DAPH1 and DAPH2. Gefitinib 168-175 epidermal growth factor receptor Rattus norvegicus 36-40 34830377-4 2021 Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs), including erlotinib, gefitinib, and osimertinib, are effective therapeutic agents in EGFR-mutated NSCLC. Gefitinib 74-83 epidermal growth factor receptor Rattus norvegicus 41-45 34830377-4 2021 Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs), including erlotinib, gefitinib, and osimertinib, are effective therapeutic agents in EGFR-mutated NSCLC. Gefitinib 74-83 epidermal growth factor receptor Rattus norvegicus 138-142 29396379-5 2018 These outcomes are comparable to the use of a controlled-release injectable thermosensitive hydrogel of gefitinib to block EGFR activity in a puncture-induced rat model. Gefitinib 104-113 epidermal growth factor receptor Rattus norvegicus 123-127 35183859-8 2022 Owing to the turn-on response of GN3 to EGFR in tumor cells, and the competitive replacement behavior to the EGFR inhibitor gefitinib, these probes have the potential to be used for fluorescence imaging of cells overexpressing EGFR. Gefitinib 124-133 epidermal growth factor receptor Rattus norvegicus 109-113 35183859-8 2022 Owing to the turn-on response of GN3 to EGFR in tumor cells, and the competitive replacement behavior to the EGFR inhibitor gefitinib, these probes have the potential to be used for fluorescence imaging of cells overexpressing EGFR. Gefitinib 124-133 epidermal growth factor receptor Rattus norvegicus 227-231 32370496-0 2020 EGFR Inhibitor Gefitinib Induces Cardiotoxicity through the Modulation of Cardiac PTEN/Akt/FoxO3a Pathway and Reactive Metabolites Formation: In Vivo and In Vitro Rat Studies. Gefitinib 15-24 epidermal growth factor receptor Rattus norvegicus 0-4 32111605-5 2020 Therefore, we sought to determine whether EGFR signaling was involved in opioid tolerance and if EGFR and PDGFR signaling could induce pain in rats.We found that gefitinib, an EGFR antagonist, eliminated morphine tolerance. Gefitinib 162-171 epidermal growth factor receptor Rattus norvegicus 42-46 32111605-5 2020 Therefore, we sought to determine whether EGFR signaling was involved in opioid tolerance and if EGFR and PDGFR signaling could induce pain in rats.We found that gefitinib, an EGFR antagonist, eliminated morphine tolerance. Gefitinib 162-171 epidermal growth factor receptor Rattus norvegicus 97-101 32111605-5 2020 Therefore, we sought to determine whether EGFR signaling was involved in opioid tolerance and if EGFR and PDGFR signaling could induce pain in rats.We found that gefitinib, an EGFR antagonist, eliminated morphine tolerance. Gefitinib 162-171 epidermal growth factor receptor Rattus norvegicus 97-101 33849825-12 2021 Lavage of gefitinib, but not erlotinib, can be used to establish models of epidermal growth factor receptor inhibitor-related rashes in BN rats. Gefitinib 10-19 epidermal growth factor receptor Rattus norvegicus 75-107 33269993-1 2021 Gefitinib, the first approved inhibitor for oral epidermal growth factor receptor (EGFR), has been proved to be effective in non-small cell lung cancer with EGFR mutation. Gefitinib 0-9 epidermal growth factor receptor Rattus norvegicus 49-81 33269993-1 2021 Gefitinib, the first approved inhibitor for oral epidermal growth factor receptor (EGFR), has been proved to be effective in non-small cell lung cancer with EGFR mutation. Gefitinib 0-9 epidermal growth factor receptor Rattus norvegicus 83-87 33269993-1 2021 Gefitinib, the first approved inhibitor for oral epidermal growth factor receptor (EGFR), has been proved to be effective in non-small cell lung cancer with EGFR mutation. Gefitinib 0-9 epidermal growth factor receptor Rattus norvegicus 157-161 33025329-1 2020 Gefitinib (Iressa), is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), used in the targeted treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). Gefitinib 0-9 epidermal growth factor receptor Rattus norvegicus 35-67 33025329-1 2020 Gefitinib (Iressa), is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), used in the targeted treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). Gefitinib 0-9 epidermal growth factor receptor Rattus norvegicus 69-73 33025329-1 2020 Gefitinib (Iressa), is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), used in the targeted treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). Gefitinib 11-17 epidermal growth factor receptor Rattus norvegicus 35-67 33025329-1 2020 Gefitinib (Iressa), is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), used in the targeted treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). Gefitinib 11-17 epidermal growth factor receptor Rattus norvegicus 69-73 32370496-1 2020 Gefitinib (GEF) is a selective inhibitor of the epidermal growth factor receptor (EGFR) used to treat non-small cell lung cancer. Gefitinib 0-9 epidermal growth factor receptor Rattus norvegicus 48-80 32370496-1 2020 Gefitinib (GEF) is a selective inhibitor of the epidermal growth factor receptor (EGFR) used to treat non-small cell lung cancer. Gefitinib 0-9 epidermal growth factor receptor Rattus norvegicus 82-86 32370496-1 2020 Gefitinib (GEF) is a selective inhibitor of the epidermal growth factor receptor (EGFR) used to treat non-small cell lung cancer. Gefitinib 11-14 epidermal growth factor receptor Rattus norvegicus 48-80 32370496-1 2020 Gefitinib (GEF) is a selective inhibitor of the epidermal growth factor receptor (EGFR) used to treat non-small cell lung cancer. Gefitinib 11-14 epidermal growth factor receptor Rattus norvegicus 82-86 31264901-6 2020 Indices of pulmonary hypertension were measured in rats treated with the epidermal growth factor receptor inhibitor gefitinib. Gefitinib 116-125 epidermal growth factor receptor Rattus norvegicus 73-105 31264901-8 2020 Consistently, chronic hypoxia augmented endothelin-1-induced superoxide production through epidermal growth factor receptor signaling, and rats treated chronically with gefitinib displayed reduced right ventricular pressure and diminished arterial remodeling. Gefitinib 169-178 epidermal growth factor receptor Rattus norvegicus 91-123 29396379-8 2018 These findings thus provide evidence that suppression of EGFR by the FDA-approved drug gefitinib can protect IVD degeneration in rats, implying the potential application of gefitinib as a small molecule drug for treating IVD degeneration. Gefitinib 87-96 epidermal growth factor receptor Rattus norvegicus 57-61 29396379-8 2018 These findings thus provide evidence that suppression of EGFR by the FDA-approved drug gefitinib can protect IVD degeneration in rats, implying the potential application of gefitinib as a small molecule drug for treating IVD degeneration. Gefitinib 173-182 epidermal growth factor receptor Rattus norvegicus 57-61 29228391-7 2018 This reduced HB-EGF/EGFR was essentially responsible for arsenic-induced astrocyte damage, obvious from a recombinant-HB-EGF-mediated recovery in GFAP levels and astrocyte morphology and reduction in astrocyte apoptosis, and the reverse by gefitinib. Gefitinib 240-249 epidermal growth factor receptor Rattus norvegicus 20-24 29228391-6 2018 Furthermore, we observed that recombinant-HB-EGF cotreatment with arsenic blocked reduction in HB-EGF, secreted-HB-EGF and phospho-EGFR, which could be reversed by EGFR-inhibitor, gefitinib, suggesting that arsenic attenuated an HB-EGF/EGFR loop in astrocytes. Gefitinib 180-189 epidermal growth factor receptor Rattus norvegicus 164-168 29228391-6 2018 Furthermore, we observed that recombinant-HB-EGF cotreatment with arsenic blocked reduction in HB-EGF, secreted-HB-EGF and phospho-EGFR, which could be reversed by EGFR-inhibitor, gefitinib, suggesting that arsenic attenuated an HB-EGF/EGFR loop in astrocytes. Gefitinib 180-189 epidermal growth factor receptor Rattus norvegicus 164-168 27669229-0 2016 The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models. Gefitinib 54-63 epidermal growth factor receptor Rattus norvegicus 4-36 27669229-0 2016 The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models. Gefitinib 54-63 epidermal growth factor receptor Rattus norvegicus 38-42 27669229-2 2016 The selective EGFR inhibitor Gefitinib was found to prevent hepatocarcinogenesis in rat cirrhotic livers. Gefitinib 29-38 epidermal growth factor receptor Rattus norvegicus 14-18 27669229-10 2016 Thus, EGFR inhibition by Gefitinib diminishes chemical and hormonal also induced hepatocarcinogenesis in the initiation stage in the non-cirrhotic liver. Gefitinib 25-34 epidermal growth factor receptor Rattus norvegicus 6-10 23559083-8 2013 In most thyroid cancer cell lines, gefitinib significantly inhibited Akt phosphorylation by inhibiting EGFR activation, but it had limited or no effect on ERK phosphorylation. Gefitinib 35-44 epidermal growth factor receptor Rattus norvegicus 103-107 25788532-4 2015 Administration of gefitinib, a highly selective EGFR inhibitor, prevented renal dysfunction, reduced urine microalbumin, and inhibited activation of renal interstitial fibroblasts and expression of extracellular proteins. Gefitinib 18-27 epidermal growth factor receptor Rattus norvegicus 48-52 23559083-5 2013 DESIGN: We tested the effect of the EGFR tyrosine kinase inhibitor gefitinib in a panel of thyroid cancer cell lines. Gefitinib 67-76 epidermal growth factor receptor Rattus norvegicus 36-40 23559083-6 2013 RESULTS: We found that in most of the cell lines, although gefitinib inhibited EGFR phosphorylation, it was poorly effective in reducing cell viability. Gefitinib 59-68 epidermal growth factor receptor Rattus norvegicus 79-83 26677863-2 2016 Here, we explored the therapeutic effect of gefitinib, a specific inhibitor of EGFR, on the development and progression of peritoneal fibrosis in a rat model. Gefitinib 44-53 epidermal growth factor receptor Rattus norvegicus 79-83 26677863-5 2016 Gefitinib treatment abrogated the increased phosphorylation of EGFR, Smad3, signal transducer and activator of transcription 3, and NF-kappaB during peritoneal fibrosis; it also inhibited the accompanying overproduction of TGF-beta1 and proinflammatory cytokines and the infiltration of macrophages to the injured peritoneum. Gefitinib 0-9 epidermal growth factor receptor Rattus norvegicus 63-67 23559083-12 2013 CONCLUSIONS: These results indicate that thyroid cancer resistance to gefitinib is due to the constitutive activation of the mitogenic pathway by either signals downstream of EGFR or other tyrosine kinase receptors. Gefitinib 70-79 epidermal growth factor receptor Rattus norvegicus 175-179 22967907-7 2012 RESULTS: In the MH1C1 hepatocarcinoma cells, stimulation with PGE2 or PGF2alpha caused phosphorylation of the EGFR, Akt, and ERK, which could be blocked by the EGFR tyrosine kinase inhibitor gefitinib. Gefitinib 191-200 epidermal growth factor receptor Rattus norvegicus 110-114 23632456-5 2013 Intraventricular infusion of the ErbB1 inhibitors ZD1839 and PD153035 in these animals ameliorated the deficits in startle response and prepulse inhibition in a dose-dependent manner. Gefitinib 50-56 epidermal growth factor receptor Rattus norvegicus 33-38 22967907-7 2012 RESULTS: In the MH1C1 hepatocarcinoma cells, stimulation with PGE2 or PGF2alpha caused phosphorylation of the EGFR, Akt, and ERK, which could be blocked by the EGFR tyrosine kinase inhibitor gefitinib. Gefitinib 191-200 epidermal growth factor receptor Rattus norvegicus 160-164 21982874-0 2012 Modulation of gene expression and cell-cycle signaling pathways by the EGFR inhibitor gefitinib (Iressa) in rat urinary bladder cancer. Gefitinib 86-95 epidermal growth factor receptor Rattus norvegicus 71-75 21982874-0 2012 Modulation of gene expression and cell-cycle signaling pathways by the EGFR inhibitor gefitinib (Iressa) in rat urinary bladder cancer. Gefitinib 97-103 epidermal growth factor receptor Rattus norvegicus 71-75 21887704-3 2011 Here, we show that administration of an EGFR-specific small-molecule inhibitor, gefitinib, into 1-month-old rats for 7 days produced profound defects in long bone growth plate cartilage characterized by epiphyseal growth plate thickening and massive accumulation of hypertrophic chondrocytes. Gefitinib 80-89 epidermal growth factor receptor Rattus norvegicus 40-44 22450006-0 2012 Epidermal growth factor receptor-tyrosine kinase inhibitor (gefitinib) augments pneumonitis, but attenuates lung fibrosis in response to radiation injury in rats. Gefitinib 60-69 epidermal growth factor receptor Rattus norvegicus 0-32 22450006-1 2012 BACKGROUND: Gefitinib, an inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, has been reported to be associated with interstitial lung disorders, and their high incidence and mortality have become a matter of great concern, especially in Japan. Gefitinib 12-21 epidermal growth factor receptor Rattus norvegicus 39-71 22450006-1 2012 BACKGROUND: Gefitinib, an inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, has been reported to be associated with interstitial lung disorders, and their high incidence and mortality have become a matter of great concern, especially in Japan. Gefitinib 12-21 epidermal growth factor receptor Rattus norvegicus 73-77 22450006-5 2012 RESULTS: Gefitinib treatment increased the infiltration of inflammatory cells, which produced more pro-inflammatory cytokines (IL-6, IL-1beta), in the lungs of the irradiated rats on days 15 and 57, while gefitinib treatment reduced collagen content of the lungs in irradiated rats and decreased proliferation and EGFR expression in the lung fibroblasts from irradiated rats on day 57. Gefitinib 9-18 epidermal growth factor receptor Rattus norvegicus 314-318 18413814-6 2008 EXPERIMENTAL DESIGN: Rats received azoxymethane or saline, and standard chow or chow supplemented with gefitinib, an EGFR inhibitor, for 44 weeks. Gefitinib 103-112 epidermal growth factor receptor Rattus norvegicus 117-121 19850946-4 2010 MEASUREMENTS AND MAIN RESULTS: The EGFR inhibitors gefitinib, erlotinib, and lapatinib inhibited the EGF-induced proliferation of pulmonary arterial smooth muscle cells. Gefitinib 51-60 epidermal growth factor receptor Rattus norvegicus 35-39 20962455-4 2010 Subchronic administration of the ErbB1 inhibitor ZD1839 to the cerebroventricle of rats receiving neonatal hippocampal lesioning ameliorated deficits in prepulse inhibition as well as those in the latent inhibition of tone-dependent fear learning. Gefitinib 49-55 epidermal growth factor receptor Rattus norvegicus 33-38 18519677-8 2008 These effects were biologically relevant, as the EGFR kinase inhibitors PKI166, gefitinib, and AEE788 inhibited cell growth induced by various constitutively active mutants of RET in thyroid cancer cells as well as NIH3T3 cells. Gefitinib 80-89 epidermal growth factor receptor Rattus norvegicus 49-53 21925118-2 2011 The EGFR kinase inhibitor gefitinib attenuates glomerular fibrosis in hypertensive rats whereas dominant-negative EGFR attenuates interstitial fibrosis in mouse with acute renal ischemia. Gefitinib 26-35 epidermal growth factor receptor Rattus norvegicus 4-8 21925118-12 2011 We concluded that gefitinib attenuates TGF-beta1-induced cell mitogenesis via the EGFR-ERK1/2/p38 kinase pathway in NRK-49F cells. Gefitinib 18-27 epidermal growth factor receptor Rattus norvegicus 82-86 21369704-0 2011 Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: dose dependency and modulation of biomarkers. Gefitinib 31-37 epidermal growth factor receptor Rattus norvegicus 16-20 18413814-9 2008 RESULTS: EGFR inhibition with gefitinib decreased the incidence of flat dysplastic ACF from 66% to 36% and tumors from 71% to 22% (P < 0.05). Gefitinib 30-39 epidermal growth factor receptor Rattus norvegicus 9-13 18375820-1 2008 The ability of the epidermal growth factor receptor inhibitor gefitinib (Iressa) to prevent/treat methylnitrosourea (MNU)-induced mammary cancers and to modulate biomarkers in female Sprague-Dawley rats was examined. Gefitinib 62-71 epidermal growth factor receptor Rattus norvegicus 19-51 18375820-1 2008 The ability of the epidermal growth factor receptor inhibitor gefitinib (Iressa) to prevent/treat methylnitrosourea (MNU)-induced mammary cancers and to modulate biomarkers in female Sprague-Dawley rats was examined. Gefitinib 73-79 epidermal growth factor receptor Rattus norvegicus 19-51 18180313-8 2008 Treatment of prostate epithelial cells in vitro under normoxic conditions also increased HIF-1alpha, and this could be blocked if epidermal growth factor receptor (EGFR) signaling was blocked with gefitinib. Gefitinib 197-206 epidermal growth factor receptor Rattus norvegicus 130-162 18630690-11 2008 Gefitinib also reduced the expression of EGFR in the lungs. Gefitinib 0-9 epidermal growth factor receptor Rattus norvegicus 41-45 18630690-12 2008 CONCLUSION: Acrolein increases the expression of MUC5AC through activating EGFR, which indicates that EGFR-TKI such as gefitinib can be useful in the treatment of mucus hypersecretion by regulating the signal transduction pathways of EGFR. Gefitinib 119-128 epidermal growth factor receptor Rattus norvegicus 75-79 18630690-12 2008 CONCLUSION: Acrolein increases the expression of MUC5AC through activating EGFR, which indicates that EGFR-TKI such as gefitinib can be useful in the treatment of mucus hypersecretion by regulating the signal transduction pathways of EGFR. Gefitinib 119-128 epidermal growth factor receptor Rattus norvegicus 102-106 18630690-12 2008 CONCLUSION: Acrolein increases the expression of MUC5AC through activating EGFR, which indicates that EGFR-TKI such as gefitinib can be useful in the treatment of mucus hypersecretion by regulating the signal transduction pathways of EGFR. Gefitinib 119-128 epidermal growth factor receptor Rattus norvegicus 102-106 18180313-8 2008 Treatment of prostate epithelial cells in vitro under normoxic conditions also increased HIF-1alpha, and this could be blocked if epidermal growth factor receptor (EGFR) signaling was blocked with gefitinib. Gefitinib 197-206 epidermal growth factor receptor Rattus norvegicus 164-168 16988945-2 2006 Gefitinib, a specific EGFR inhibitor, has shown to reduce significantly, although not completely, HCC formation in rat cirrhotic liver. Gefitinib 0-9 epidermal growth factor receptor Rattus norvegicus 22-26 17003482-2 2006 We previously reported that an epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), significantly inhibited the abnormal growth of biliary epithelial cells of PCK rats in vitro. Gefitinib 91-100 epidermal growth factor receptor Rattus norvegicus 31-63 17043666-4 2006 Urinary bladders from adult female rats were distended in vivo with medium containing the EGFR inhibitor ZD1839 (gefitinib, Iressa). Gefitinib 105-111 epidermal growth factor receptor Rattus norvegicus 90-94 17003482-2 2006 We previously reported that an epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), significantly inhibited the abnormal growth of biliary epithelial cells of PCK rats in vitro. Gefitinib 102-108 epidermal growth factor receptor Rattus norvegicus 31-63 15660382-0 2005 Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Gefitinib 0-9 epidermal growth factor receptor Rattus norvegicus 14-18 16488438-9 2006 JB cells had the highest expression of EGFR protein and also the most profound response to Iressa (gefitinib), an EGFR inhibitor (IC50 < 1 microm). Gefitinib 91-97 epidermal growth factor receptor Rattus norvegicus 114-118 16488438-9 2006 JB cells had the highest expression of EGFR protein and also the most profound response to Iressa (gefitinib), an EGFR inhibitor (IC50 < 1 microm). Gefitinib 99-108 epidermal growth factor receptor Rattus norvegicus 39-43 16488438-9 2006 JB cells had the highest expression of EGFR protein and also the most profound response to Iressa (gefitinib), an EGFR inhibitor (IC50 < 1 microm). Gefitinib 99-108 epidermal growth factor receptor Rattus norvegicus 114-118 15660382-3 2005 Herein, we developed an experimental model of cirrhosis giving rise to HCC and tested the antitumoral effect of gefitinib, a selective EGFR tyrosine kinase inhibitor, in this model. Gefitinib 112-121 epidermal growth factor receptor Rattus norvegicus 135-139 15660382-8 2005 In rats treated with gefitinib, the number of HCC nodules was significantly lower than in untreated rats (18.1 +/- 2.4 vs. 3.7 +/- 0.45; P < .05), while EGFR was activated to a lesser extent in the diseased and tumoral tissues of these animals compared with untreated rats. Gefitinib 21-30 epidermal growth factor receptor Rattus norvegicus 156-160 15660382-10 2005 In conclusion, the blockade of EGFR activity by gefitinib has an antitumoral effect on the development of HCC in DEN-exposed rats, suggesting that it may provide benefit for the chemoprevention of HCC. Gefitinib 48-57 epidermal growth factor receptor Rattus norvegicus 31-35 15033924-7 2004 Gefitinib, an EGFR-tyrosine kinase inhibitor, given concomitantly with L-NAME, normalized MAPK activation and collagen I expression and prevented the decline of renal function and the development of fibrosis. Gefitinib 0-9 epidermal growth factor receptor Rattus norvegicus 14-18